However, the PI3K/AKT/mTOR pathway is not universally dysregulated across all cancers, and PAM inhibitors are only effective in cancers that rely on the PI3K/AKT/mTOR pathway as a driver [43,44]. This evidence concerns the gene AKT1 and cancer.